Market Cap: $232.1M
IN
InflaRx N.V.
IFRX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $232.1M
InflaRx N.V. Leverages Drug Development Pipeline Amidst Industry Shifts InflaRx N.V. stands at a critical junction in the biotechnology sector, focusing on the advancement of its innovative drug devel…
### InflaRx N.V. Targets IL-1α Pathway in Novel Therapeutic Approach InflaRx N.V. focuses on the innovative treatment of severe inflammatory diseases by developing its proprietary biological drugs aim…
InflaRx N.V. Prioritizes Key Drug Development Amid Cost-Cutting Measures InflaRx N.V. announces a strategic initiative aimed at reducing costs and streamlining operations to extend its financial runwa…
InflaRx N.V. Prioritizes Izicopan Amid Financial Restructuring InflaRx N.V. announces a strategic initiative aimed at reducing costs and streamlining operations to extend its financial runway. In a de…
InflaRx N.V. Advances in Drug Development for Rare Inflammatory Diseases InflaRx N.V., a biopharmaceutical company focused on the development of therapeutics for inflammatory diseases, continues to ma…
InflaRx Advances Clinical Research in Inflammatory Diseases InflaRx N.V. continues to make significant strides in the development of its innovative treatments for inflammatory diseases. The company fo…
InflaRx N.V. Advances in Anti-Inflammatory Therapy Development InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on developing therapies for severe inflammatory diseases. The company i…
InflaRx N.V. Advances in Novel Therapeutics for Inflammatory Diseases InflaRx N.V., a clinical-stage biopharmaceutical company, is making significant strides in developing innovative treatments for in…
InflaRx N.V. Sees Decline in Short Interest, Indicating Shifts in Investor Sentiment InflaRx N.V., a biopharmaceutical company specializing in immune-mediated diseases, reports a significant decline i…
InflaRx NV Shows Signs of Improved Investor Sentiment Amid Decreasing Short Interest InflaRx N.V., a biopharmaceutical company focusing on developing therapies for severe inflammatory diseases, witnes…
InflaRx N.V. Advances in Immunotherapy Development Amid Competitive Landscape InflaRx N.V., a biopharmaceutical company focused on the development of therapeutics for serious inflammatory diseases, is…
Biogen's Strategic Move in Immunology: A License Agreement with Vanqua Bio Biogen Inc. takes a significant step forward in the biopharmaceutical landscape through a new licensing agreement with Vanqua…
Biogen's Strategic Partnership with Vanqua Bio: A Leap Forward in Immunology Biogen Inc. has recently solidified its position in the biopharmaceutical landscape through a significant licensing agreeme…
InflaRx Faces Setback in Pyoderma Gangrenosum Trial InflaRx N.V. announces a pivotal development regarding its Phase 3 trial of vilobelimab for treating pyoderma gangrenosum (PG), a severe inflammator…
InflaRx N.V. Halts Phase 3 Trial for Vilobelimab in Pyoderma Gangrenosum Due to Futility InflaRx N.V. recently faces a major setback in its clinical development pipeline as the Independent Data Monito…